Atnaujinkite slapukų nuostatas

Handbook of Hematologic Malignancies 3rd New edition [Minkštas viršelis]

Edited by , Edited by , Edited by , Edited by
  • Formatas: Paperback / softback, 660 pages, aukštis x plotis: 203x127 mm, 56 Illustrations
  • Išleidimo metai: 28-Jun-2025
  • Leidėjas: Springer Publishing Co Inc
  • ISBN-10: 0826184413
  • ISBN-13: 9780826184412
Kitos knygos pagal šią temą:
Handbook of Hematologic Malignancies 3rd New editionDidesnis paveikslėlis
  • Formatas: Paperback / softback, 660 pages, aukštis x plotis: 203x127 mm, 56 Illustrations
  • Išleidimo metai: 28-Jun-2025
  • Leidėjas: Springer Publishing Co Inc
  • ISBN-10: 0826184413
  • ISBN-13: 9780826184412
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780826184412.html

Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.

This edition introduces a completely new set of challenging clinical cases, designed to rigorously test clinicians' knowledge of pathologic diagnosis and clinical presentation. With over 35 new FDA-approved indications since the second edition—featuring groundbreaking advancements such as CAR-T therapy—this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.

Key Features:

  • New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.
  • Entirely new unfolding clinical cases with board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.
  • Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.
  • Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.
  • Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.
Contributors


Preface


Abbreviations


PART I. INTRODUCTION AND OVERVIEW


1. Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses


2. ICC and WHO Classifications and Potential Future Harmonization


3. Familial/Inherited Variants and Risks of Hematologic Malignancies


4. Diagnostic Approaches to Hematologic Malignancies


5. Minimal Residual Disease Assays


6. Personalized Approach to Hematologic Malignancies


PART II. MYELOPROLIFERATIVE NEOPLASMS


7. Polycythemia Vera


8. Essential Thrombocythemia


9. Primary Myelofibrosis


10. Chronic Myelogenous Leukemia


11. Chronic Neutrophilic Leukemia


12. Systemic Mastocytosis


13. Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene
Fusion (MLN-TK)


PART III. MYELODYSPLASTIC AND BONE MARROW FAILURE SYNDROMES


14. CHIP, CCUS and Precursor States of Myeloid Neoplasms


15. Myelodysplastic Syndromes


16. Aplastic Anemia


17. Paroxysmal Nocturnal Hemoglobinuria


PART IV. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS


18. Myelodysplastic/Myeloproliferative Neoplasms


19. Chronic Myelomonocytic Leukemia


PART V. ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES


20. Acute Myeloid Leukemia


21. Secondary AML and AML-MRC


22. Acute Promyelocytic Leukemia


23. Blastic Plasmacytoid Dendritic Cell Neoplasm


PART VI. ACUTE LYMPHOID LEUKEMIA


24. B-Lymphoblastic Leukemia/Lymphoma


25. BCR-ABL1+ B-Lymphoblastic Leukemia


26. T-Cell Acute Lymphoblastic Leukemia/Lymphoma


PART VII. ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE


27. Acute Leukemia of Ambiguous Lineage


PART VIII. MATURE T- AND NK-CELL LEUKEMIA


28. T-Cell Prolymphocytic Leukemia


29. T-Cell Large Granular Lymphocytic Leukemia


30. Aggressive Natural Killer Cell Leukemia


PART IX. PLASMA CELL DISORDERS


31. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and
Plasmacytomas


32. Multiple Myeloma


33. Waldenström Macroglobulinemia


34. Immunoglobulin Light Chain Amyloidosis AL


PART X. HODGKIN LYMPHOMA


35. Hodgkin Lymphoma


PART XI. NON-HODGKIN LYMPHOMA


36. Diagnosis and Classification of Non-Hodgkin Lymphomas


PART XII. MATURE B-CELL LYMPHOMA


VERY AGGRESIVE


37. Burkitt Lymphoma


AGGRESSIVE


38. Diffuse Large B-Cell Lymphoma


39. Double-Hit Lymphoma


40. Mantle Cell Lymphoma


41. Primary Central Nervous System Lymphoma


42. HIV-Related Lymphomas


43. Follicular Lymphoma


44. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma


45. Hairy Cell Leukemia


46. Marginal Zone Lymphoma


PART XIII. MATURE T- AND NK-CELL LYMPHOMA


47. Peripheral T-Cell Lyphoma


48. Adult T-Cell Leukemia/Lymphoma


49. Anaplastic Large Cell Lymphoma


50. Extranodal Natural Killer/T-Cell Lymphoma


51. Mycosis Fungoides/Sézary Syndrome


52. Hepatosplenic T-Cell Lymphoma


PART XIV. HISTIOCYTIC/DENDRITIC CELL NEOPLASMS


53. Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman
Disease, and Histiocytic Sarcoma


54. Hemophagocytic Lymphohistiocytosis


PART XV. BONE MARROW TRANSPLANTATION


55. Autologous Hematopoietic Cell Transplantation


56. Allogeneic Hematopoietic Cell Transplantation


PART XVI. NEW CELLULAR IMMUNOTHERAPY


57. CAR-T Overview and Novel Cellular Therapeutic Options


58. CD19 CAR T-Cell Therapy


59. BCMA CAR T-Cell Therapy


60. Cytokine Release Syndrome and Other Toxicities Associated With Cellular
Therapies


PART XVII. EMERGENCIES IN HEMATOLOGY


61. Cancer-Associated Thrombosis in Hematologic Malignancies


62. Tumor Lysis Syndrome


63. Thrombotic Microangiopathy


64. Therapeutic Apheresis Indications


Appendix: Pathology Supplement


Index
David A. Sallman, MD, Associate Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida Morsani College of Medicine, Tampa, Florida

Ateefa Chaudhury, MD, Hematologist, New Mexico Cancer Center, Albuquerque, New Mexico

Hayder Saeed, MD, Associate member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Ling Zhang, MD, Senior Member, Professor, Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida